首页/数据集/Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer

Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer

NIAID Data Ecosystem2026-03-07 收录

转移性结直肠癌治疗

药物安全性评估

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2149306 数据链接链接失效反馈

官方服务：

资源简介：

To assess the safety profile of bevacizumab in combination with chemotherapy for the treatment of metastatic colorectal cancer

应用场景：

创建时间：

2013-08-15

药物不良反应监测

药物安全性评估

This study analyzed adverse drug event (ADE) signals associated with metreleptin using the FDA Adverse Event Reporting System (FAERS) to provide insights for safe clinical use. Data from 1 January 201

DataCite Commons2026-05-04 更新120

A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

转移性结直肠癌治疗

肿瘤药物临床试验

This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI. The randomized,

NIAID Data Ecosystem60

FORECAST 1. Feasibility of using Organoid Response to find Effective Treatments for patients with Colorectal cancer After failure of Standard Therapy

类器官药物筛选

转移性结直肠癌治疗

Interventions: This feasibility study involves the collection of fresh tumour tissue from patients with Metastatic Colorectal Cancer ( mCRC) for the purposes of establishing organoid model cultures.Pa

NIAID Data Ecosystem40

Rates of systemic adverse effects of head-to-head studies (direct comparison).

药物安全性评估

癌症治疗不良反应

Nr: Not reported. *Data from CATT appendix: they refer to duodenal ulcer haemorrhage, gastric ulcer haemorrhage, (lower) gastrointestinal haemorrhage, rectal haemorrhage. #Rates refer mainly to pneumo

NIAID Data Ecosystem60

Local and Solicited Systemic Reactogenicity.

疫苗反应原性

药物安全性评估

Local and Solicited Systemic Reactogenicity.

NIAID Data Ecosystem40